Mesenchymal stem cells and connective tissue diseases: From bench to bedside

Area of Science:

• Immunology
• Regenerative Medicine
• Rheumatology

Background:

• Connective tissue diseases (CTDs) involve complex immune dysregulation.
• Mesenchymal stem cells (MSCs) possess immunomodulatory properties.
• MSCs offer a potential therapeutic strategy for immune-mediated disorders like CTDs.

Purpose of the Study:

• To review the immunoregulatory mechanisms of MSCs.
• To summarize preclinical and clinical evidence of MSC-based therapies for CTDs.
• To identify challenges and future research directions for MSC therapy in CTDs.

Main Methods:

• Review of preclinical studies in CTD animal models.
• Analysis of clinical trial data (pilot, cohort, RCTs) in CTD patients.
• Examination of studies on MSCs in systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), systemic sclerosis (SSc), primary Sjögren's syndrome (pSS), and idiopathic inflammatory myopathies (IIM).

Main Results:

• MSCs demonstrated symptomatic and histologic improvements in CTD animal models.
• Pilot studies and RCTs show promise for MSC therapy in severe, drug-resistant SLE, RA, and SSc.
• Early studies in pSS and IIM also show encouraging outcomes.
• Efficacy varies based on MSC delivery route, timing, origin, and dosage.

Conclusions:

• MSCs are a promising immunomodulatory therapy for CTDs.
• Further research is required to optimize MSC therapy parameters and drug combinations.
• Cell engineering approaches may enhance MSC therapeutic applications for CTDs.